Amyloid Clearance: Check. Cognitive Benefit: Um … Maybe.
Plaque-busting antibodies reset the time course of amyloid accumulation, but so far provide only hints of a clinical benefit in mild AD. Good news: once gone, plaque stays gone for a while.
ALL NEWS
5781 RESULTS
Sort By:
- Most Recent
- Most Commented
Astroglial Markers Poised for Stardom?
A new PET tracer. Plasma glial fibrillary acidic protein. Two new, promising surrogates for astrogliosis are filling in the Alzheimer’s biomarker toolbox. Both reflect Aβ amyloid better than they do tau tangles.
Shuttle Unloads More Gantenerumab Into the Brain
New data presented at the AD/PD conference offer the first evidence that a brain-shuttle strategy can work in people; the lecanemab and aducanumab antibody programs offer small updates.
New Guidelines Proposed for Alzheimer's Disease Postmortem Diagnosis
An international group of researchers* have agreed upon recommendations to revise the criteria for postmortem diagnosis of Alzheimer’s disease (AD)...
Clinicians from Developing Nations Discuss Dementia in Their Populations
As life expectancy increases in countries such as Nigeria, Brazil, China, and others, so does the number of people with dementia. How to provide modern care for them?
Clinical Trials in COVID Era: How To Keep Moving Forward
By shifting to home nursing and telemedicine, clinical researchers kept inching ahead during lockdowns.
Umibecestat-Driven Cognitive Decline Is Reversible
Subtle memory deficits resolved after volunteers stopped taking the Novartis BACE inhibitor.
FTD Fluid Markers for Degeneration: Check. For Pathology: Not Yet.
As FTD consortia chase biomarkers, they see plasma NfL and neuronal pentraxin-2—which reflect neurodegeneration—change before symptoms. Trials nudge progranulin and poly-DP. Still needed: more markers of the pathophysiology that unfolds in the brain.
International Conference on Alzheimer's and Parkinson's Diseases 2021 (Virtual Meeting)
Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit Astroglial Markers Poised for Stardom? Shuttle Unloads More Gantenerumab Into the Brain N-Terminal Tau Antibodies Fade, Mid-Domain Ones Push to the Fore Where to Now, Phospho-Tau? Clinicians from ...
Michael J. Fox Foundation Launches Big PD Biomarker Study
A $40 million multicenter biomarker study for Parkinson disease progression is off and running, with enrollment underway at 10 of 18 sites in the U.S. and Europe. In design and operation, the Parkinson's Progression Markers Initiative (PPMI) ...
ALS Ice Bucket Challenge Returns for a Repeat Performance in 2015
Last year's ice bucket challenge for amyotrophic lateral sclerosis netted $220 million in donations for ALS charities, and the 2015 challenge is off to a strong start with $100,000 from Major League Baseball. Alzforum looks at how all that money is ...
COVID-19 Worsens Neurological Problems, Delirium
At AD/PD 2021, clinicians discussed neurological symptoms and brain tissue damage in older people who died from COVID-19.
Cortical Hubs to Rich Clubs—Linking Brain Connectivity to Function
If you find it hard to keep up with Facebook, LinkedIn, and other social networks, spare a thought for the brain. With 100 to 500 trillion synaptic connections, the human brain dwarfs all of them. How do those connections work to formulate thought, recall ...
Task Force Focuses on Tracing Brain Amyloid
Online training for use of Amyvid, the first FDA-approved Aβ imaging ligand, is now up and running,even as a task force convened by the Society of Nuclear Medicine and the Alzheimer's Association scrambles to formulate some expert guidelines on how ...
Brain Training—Plain Gaming, or a New Vein for Preclinical Research?
If you listen to National Public Radio, watch TV, or surf the Web, chances are you have come across commercials enticing you to “improve your memory” and “unlock your inner genius” with “brain training developed by neuroscientists.” In search of solid ...
Current Filters
- Date Range : All x